Sign up for the QMED & MD+DI Daily newsletter.
The Danbury, CT-based company said it was picking up the V-Go wearable $10 million.
May 17, 2022
1 Min Read
Image courtesy of Stuart Burford / Alamy Stock Photo
MannKind is acquiring Zealand Pharma’s wearable V-Go Insulin Delivery Device to expand its diabetes offerings. The deal is expected to close this month.
The Danbury, CT-based company said it was putting up $10 million with the potential for additional sales-based milestones plus the cost of certain inventory.
MannKind said V-Go is a once-daily, wearable, insulin delivery device that helps provide blood sugar control for everyday lifestyles. V-Go is worn like a patch and eliminates the need for taking multiple daily shots.
“The easy click-and-go mechanism of V-Go and its ability to be flexibly placed on your body each day aligns with our mission of providing products that allow patients living with diabetes to experience life without limits,” said Alejandro Galindo, Executive Vice President, Endocrine Business Unit for MannKind Corporation. “V-Go joins our ultra-rapid-acting inhaled insulin product, Afrezza, in expanding MannKind’s portfolio of products that change the way diabetes is treated.”
You May Also Like
BioSig Cuts a Substantial Number of PositionsFeb 20, 2024|2 Min Read
Philips BrightView Imaging System Hit with Class I RecallFeb 20, 2024|2 Min Read
Medtronic Exits Ventilator Market, Raises FY24 OutlookFeb 20, 2024|4 Min Read
Medical Device Suppliers Unite to Form the WCDAFeb 20, 2024